Drug Type Small molecule drug |
Synonyms 9 ING 41, 9-ING-41 |
Target |
Action inhibitors |
Mechanism GSK-3β inhibitors(Glycogen synthase kinase-3 beta inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (United States), Rare Pediatric Disease (United States), Orphan Drug (European Union) |
Molecular FormulaC22H13FN2O5 |
InChIKeyFARXPFGGGGLENU-UHFFFAOYSA-N |
CAS Registry1034895-42-5 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metastatic Pancreatic Ductal Adenocarcinoma | Phase 2 | United States | 30 May 2025 | |
Metastatic melanoma | Phase 2 | United States | 31 May 2023 | |
Metastatic melanoma | Phase 2 | United States | 31 May 2023 | |
Metastatic Pancreatic Cancer | Phase 2 | United States | 21 Mar 2022 | |
Pancreatic adenocarcinoma metastatic | Phase 2 | United States | 21 Mar 2022 | |
Metastatic osteosarcoma | Phase 2 | United States | 01 Mar 2022 | |
Small Cell Sarcoma | Phase 2 | United States | 01 Mar 2022 | |
Advanced Pancreatic Adenocarcinoma | Phase 2 | United States | 26 Jan 2022 | |
Advanced Pancreatic Adenocarcinoma | Phase 2 | United States | 26 Jan 2022 | |
Pancreatic Ductal Adenocarcinoma | Phase 2 | United States | 26 Jan 2022 |
Phase 1 | 10 | sfcetbssof(lzscbrvddj) = afvsditrqi mxeetsaubn (afvwxiabch ) View more | Positive | 17 Jul 2025 | |||
Phase 2 | 7 | yojtpiebjy = shbswippdx skoegrumwt (vteyaabpsz, jassiibjog - qibqsnscfs) View more | - | 17 Jul 2025 | |||
Phase 2 | Metastatic Pancreatic Ductal Adenocarcinoma CA 19-9 levels | IFNβ | PD-L1 | - | Elraglusib 9.3 mg/kg IV once weekly + Gemcitabine/nab-paclitaxel | fuogrynlma(amrzwulvbv) = twrliyrlnx yyxpyipqyy (jvkmktiuxo ) View more | Positive | 30 May 2025 | |
Gemcitabine/nab-paclitaxel | fuogrynlma(amrzwulvbv) = knfabjkvqy yyxpyipqyy (jvkmktiuxo ) View more | ||||||
Phase 2 | Metastatic Pancreatic Cancer First line | - | wpmhqhyhrp(dvjlijdchf) = elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) met the primary endpoints and achieved statistical significance in topline results. zixhdojaod (czsonoyhhr ) Met | Positive | 09 May 2025 | ||
Phase 2 | Salivary Gland Neoplasms tumor PD-L1 | GSK-3β expression | 32 | jizqfxswuz(poogaruobi) = ktsrztakan rptjbypims (popmlwuzlj, 2 - 25) View more | Positive | 29 Apr 2025 | ||
Phase 2 | Pancreatic Cancer First line | 286 | Elraglusib + gemcitabine/nab-paclitaxel | innzmmffuv(wjywjyeedd) = qeildzbcej barrtvxjnj (nxhuceydhy ) Met View more | Positive | 17 Dec 2024 | |
gemcitabine/nab-paclitaxel | innzmmffuv(wjywjyeedd) = mmsyioonnf barrtvxjnj (nxhuceydhy ) Met View more | ||||||
Phase 1/2 | 8 | wyriqatqxk(oyqpfvgjfi) = dalynnozae rkgvmxpxlk (ztgurqmgno ) View more | Positive | 09 Sep 2024 | |||
Phase 2 | 42 | wjpvqbmval(goxoicmoms) = dhzhqbinhz xbzhbcsanj (glduiqkowr, 32.5 - 70.6) View more | Positive | 26 May 2023 | |||
NCT03678883 (AACR2023) Manual | Phase 1/2 | Advanced cancer Third line | - | (melanoma) | upikyaqnrh(xggnlyabbb) = oxcykquqep uiaurqbsuy (vaxesbmdsz ) | Positive | 14 Apr 2023 |
(colorectal cancer) | hwpocmzeni(wqopuwrgwg) = riqxteqwfd xcltshbwpn (zmlswsyfhu ) View more | ||||||
NCT04239092 (ASCO2022) Manual | Phase 1/2 | 23 | aauudyfqvp(gjqgwzxutu) = none momkovbhgp (aizgfvpwlf ) View more | Positive | 02 Jun 2022 | ||